ECSP10010336A - Derivados de piridina - Google Patents
Derivados de piridinaInfo
- Publication number
- ECSP10010336A ECSP10010336A EC2010010336A ECSP10010336A ECSP10010336A EC SP10010336 A ECSP10010336 A EC SP10010336A EC 2010010336 A EC2010010336 A EC 2010010336A EC SP10010336 A ECSP10010336 A EC SP10010336A EC SP10010336 A ECSP10010336 A EC SP10010336A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- disorders
- fibrosis
- pulmonary
- piridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula I, en forma libre o de sal o de solvato, en donde T1, T2, X, Ra, Rb, R8 y R9 tienen los significados que se indican en la descripción, y son útiles para el tratamiento de trastornos inflamatorios u obstructivos de las vías respiratorias, hipertensión pulmonar, fibrosis pulmonar, fibrosis hepática, enfermedades musculares y trastornos esqueléticos sistémicos. También se describen composiciones farmacéuticas que contienen los compuestos y procesos para prepararlos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08150187 | 2008-01-11 | ||
EP08168207 | 2008-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010336A true ECSP10010336A (es) | 2010-08-31 |
Family
ID=40689319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010336A ECSP10010336A (es) | 2008-01-11 | 2010-07-09 | Derivados de piridina |
Country Status (22)
Country | Link |
---|---|
US (1) | US8343966B2 (es) |
EP (1) | EP2242742B1 (es) |
JP (1) | JP5566909B2 (es) |
KR (1) | KR20100101138A (es) |
CN (1) | CN101918362B (es) |
AR (1) | AR070519A1 (es) |
AU (1) | AU2009203681B2 (es) |
BR (1) | BRPI0907611A2 (es) |
CA (1) | CA2711803A1 (es) |
CL (1) | CL2009000029A1 (es) |
CR (1) | CR11490A (es) |
EA (1) | EA201001127A1 (es) |
EC (1) | ECSP10010336A (es) |
ES (1) | ES2562447T3 (es) |
IL (1) | IL206276A0 (es) |
MA (1) | MA31947B1 (es) |
MX (1) | MX2010007606A (es) |
PE (1) | PE20091316A1 (es) |
TN (1) | TN2010000255A1 (es) |
TW (1) | TW200938536A (es) |
WO (1) | WO2009087212A2 (es) |
ZA (1) | ZA201003929B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009263037B2 (en) * | 2008-06-26 | 2011-10-06 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
JP2012527461A (ja) * | 2009-05-19 | 2012-11-08 | ダウ アグロサイエンシィズ エルエルシー | 真菌を防除するための化合物および方法 |
MX2012014537A (es) * | 2010-07-05 | 2013-02-21 | Merck Patent Gmbh | Derivados de bipiridilo utiles para el tratamiento de enfermedades inducidas por cinasa. |
WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
WO2014067962A1 (de) | 2012-10-31 | 2014-05-08 | Bayer Cropscience Ag | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
JP6433509B2 (ja) | 2014-04-24 | 2018-12-05 | ノバルティス アーゲー | ホスファチジルイノシトール3−キナーゼ阻害薬としてのアミノピラジン誘導体 |
AU2014391605A1 (en) | 2014-04-24 | 2016-10-27 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
ES2667424T3 (es) | 2014-04-24 | 2018-05-10 | Novartis Ag | Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa |
PE20190971A1 (es) | 2016-06-13 | 2019-07-09 | Glaxosmithkline Ip Dev Ltd | Compuestos quimicos |
WO2018213185A1 (en) * | 2017-05-17 | 2018-11-22 | Drexel University | Rela inhibitors for biofilm disruption |
WO2019126733A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
KR20200128531A (ko) | 2018-01-29 | 2020-11-13 | 카풀루스 테라퓨틱스, 엘엘씨 | 6원 중심 고리를 포함하는 srebp 억제제 |
CN116075307A (zh) | 2020-07-15 | 2023-05-05 | 奇斯药制品公司 | 作为alk5抑制剂的吡啶并噁嗪氨基衍生物 |
CN116096719A (zh) | 2020-07-15 | 2023-05-09 | 奇斯药制品公司 | 作为alk5抑制剂的哒嗪基氨基衍生物 |
US20240116947A1 (en) | 2020-07-15 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
EP4267584A1 (en) | 2020-12-23 | 2023-11-01 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
CN112707924A (zh) * | 2020-12-26 | 2021-04-27 | 蚌埠中实化学技术有限公司 | 一种4-胺甲基苯硼酸盐酸盐的合成方法 |
WO2023046698A1 (en) | 2021-09-21 | 2023-03-30 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
KR102556500B1 (ko) * | 2021-11-19 | 2023-07-19 | 하나제약 주식회사 | 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물 |
WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909529A (en) * | 1956-07-19 | 1959-10-20 | Merck Ag E | Process for preparing 3, 4-dihydro-1, 2-pyrano-(3, 4-c)-pyridone-(6) |
BE789099A (fr) * | 1971-09-22 | 1973-03-21 | Boehringer Sohn Ingelheim | Nouveaux derives de la pyridine et procede pour les fabriquer |
JP4272338B2 (ja) * | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
TW200417547A (en) * | 2002-07-31 | 2004-09-16 | Smithkline Beecham Corp | Compounds |
US20040142978A1 (en) * | 2002-12-12 | 2004-07-22 | Pharmacia Corporation | Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 |
AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
WO2007124288A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of cdc7 |
WO2007124546A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors 3 |
WO2007124545A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors - 2 |
WO2007124544A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors - 1 |
WO2008114157A1 (en) | 2007-03-16 | 2008-09-25 | Actelion Pharmaceuticals Ltd | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
US20100168077A1 (en) * | 2007-04-04 | 2010-07-01 | Ucb Pharma, S.A. | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof |
NZ581397A (en) | 2007-04-27 | 2012-02-24 | Astrazeneca Ab | Pyrimidine compounds for the inhibition of Eph receptors and for the treatment of cancer |
EA201000615A1 (ru) * | 2007-10-17 | 2010-12-30 | Новартис Аг | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) |
-
2009
- 2009-01-02 US US12/319,234 patent/US8343966B2/en not_active Expired - Fee Related
- 2009-01-08 AR ARP090100052A patent/AR070519A1/es not_active Application Discontinuation
- 2009-01-09 CL CL2009000029A patent/CL2009000029A1/es unknown
- 2009-01-09 KR KR1020107015161A patent/KR20100101138A/ko not_active Application Discontinuation
- 2009-01-09 PE PE2009000022A patent/PE20091316A1/es not_active Application Discontinuation
- 2009-01-09 CN CN200980102000XA patent/CN101918362B/zh not_active Expired - Fee Related
- 2009-01-09 BR BRPI0907611-5A patent/BRPI0907611A2/pt not_active IP Right Cessation
- 2009-01-09 MX MX2010007606A patent/MX2010007606A/es active IP Right Grant
- 2009-01-09 CA CA2711803A patent/CA2711803A1/en not_active Abandoned
- 2009-01-09 WO PCT/EP2009/050208 patent/WO2009087212A2/en active Application Filing
- 2009-01-09 EP EP09700450.1A patent/EP2242742B1/en active Active
- 2009-01-09 ES ES09700450.1T patent/ES2562447T3/es active Active
- 2009-01-09 JP JP2010541789A patent/JP5566909B2/ja not_active Expired - Fee Related
- 2009-01-09 AU AU2009203681A patent/AU2009203681B2/en not_active Ceased
- 2009-01-09 EA EA201001127A patent/EA201001127A1/ru unknown
- 2009-01-10 TW TW098100869A patent/TW200938536A/zh unknown
-
2010
- 2010-06-02 ZA ZA2010/03929A patent/ZA201003929B/en unknown
- 2010-06-04 TN TN2010000255A patent/TN2010000255A1/fr unknown
- 2010-06-10 CR CR11490A patent/CR11490A/es not_active Application Discontinuation
- 2010-06-10 IL IL206276A patent/IL206276A0/en unknown
- 2010-06-29 MA MA32965A patent/MA31947B1/fr unknown
- 2010-07-09 EC EC2010010336A patent/ECSP10010336A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20100101138A (ko) | 2010-09-16 |
EP2242742A2 (en) | 2010-10-27 |
EP2242742B1 (en) | 2015-12-02 |
JP5566909B2 (ja) | 2014-08-06 |
WO2009087212A3 (en) | 2009-09-24 |
IL206276A0 (en) | 2010-12-30 |
ES2562447T3 (es) | 2016-03-04 |
BRPI0907611A2 (pt) | 2015-07-21 |
TW200938536A (en) | 2009-09-16 |
US8343966B2 (en) | 2013-01-01 |
TN2010000255A1 (en) | 2011-11-11 |
MX2010007606A (es) | 2010-08-23 |
EA201001127A1 (ru) | 2011-02-28 |
WO2009087212A2 (en) | 2009-07-16 |
AU2009203681B2 (en) | 2012-08-16 |
CA2711803A1 (en) | 2009-07-16 |
AU2009203681A1 (en) | 2009-07-16 |
JP2011509277A (ja) | 2011-03-24 |
AR070519A1 (es) | 2010-04-14 |
MA31947B1 (fr) | 2010-12-01 |
ZA201003929B (en) | 2011-03-30 |
US20090215776A1 (en) | 2009-08-27 |
CN101918362B (zh) | 2013-11-27 |
CL2009000029A1 (es) | 2009-07-24 |
CR11490A (es) | 2010-08-11 |
PE20091316A1 (es) | 2009-09-24 |
CN101918362A (zh) | 2010-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP10010336A (es) | Derivados de piridina | |
CO6270321A2 (es) | Derivados de imidazo[1,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk) | |
ECSP088082A (es) | Derivados de piridazina | |
EA201001129A1 (ru) | Пиримидины в качестве ингибиторов киназы | |
CY1118909T1 (el) | Αμιδια οξαλικου οξεος ως αναστολεις νεπριλυσινης, φαρμακευτικη συνθεση αυτων και παρασκευη αυτων | |
CY1124219T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν τοπικο αναiσθητiκο οπως η βουπιβακαϊνη για τοπικη χορηγηση στο στομα ή τον φαρυγγα | |
CO6310968A2 (es) | Derivados de 3,5-diamino sustituido-n-tetrahidropirimidin/imidazolin/diazepam-2-ilidenpirazin-2-carboxamida, utiles como bloqueadores de la actividad del canal de sodio epitelial (enac) | |
EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
CO6331340A2 (es) | Pirrolo-pirimidinas y pirrolo piridinas | |
CY1115858T1 (el) | Υποκατεστημενες πιπεριδινο-διυδρο-θειενο-πυριμιδινες | |
UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
ATE517882T1 (de) | Chinolinderivate | |
CO6290683A2 (es) | Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met | |
CL2007002043A1 (es) | Compuestos derivados de pirimidinas sustituidos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, hipertension pulmonar, fibrosis pulmonar, fibro | |
CR9703A (es) | Derivados de pirazolona | |
GT200500281A (es) | Compuestos organicos. | |
CY1114200T1 (el) | Ναφθυλοοξικα οξεα | |
EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
CR10206A (es) | Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
HK1146709A1 (en) | Pharmaceutical compositions for intranasal administration comprising choline salts of succinic acid | |
CO6321280A2 (es) | Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
AR063027A1 (es) | Derivados de sulfonamida | |
CY1122596T1 (el) | Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου | |
DOP2006000287A (es) | Derivados de piperidina |